NCT00346957 - A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

April 30, 2003

Study Completion Date

April 30, 2003

Conditions

AMD

Interventions

DRUG

Anecortave acetate 30 mg

0.5ml administered onto the sclera once every six months for 24 months

DRUG

Anecortave Acetate 15 mg

0.5ml administered onto the sclera once every six months for 24 months

DRUG

Anecortave Acetate 3 mg

0.5ml administered onto the sclera once every six months for 24 months

OTHER

Anecortave Acetate Vehicle

0.5ml administered onto the sclera once every six months for 24 months